These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36688263)

  • 1. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?
    Mastorino L; Gelato F; Richiardi I; Cavaliere G; Quaglino P; Ortoncelli M; Ribero S
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):e691-e692. PubMed ID: 36688263
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful dose reduction of dupilumab in atopic dermatitis.
    Ardern-Jones MR; Buchanan EE; Njungu S; O'Driscoll D
    Br J Dermatol; 2023 Apr; 188(5):678-679. PubMed ID: 36662536
    [No Abstract]   [Full Text] [Related]  

  • 3. Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study.
    Lasheras-Pérez MA; Palacios-Diaz RD; González-Delgado VA; Cobreros LV; Pereira-Resquin Galván GO; Miquel-Miquel J; Labrandero Hoyos C; Zaragoza Ninet V; Melgosa Ramos FJ; Sánchez-Motilla JM; Navarro-Blanco F; Martín-Torregrosa D; Botella-Estrada R; Rodríguez-Serna M
    Int J Dermatol; 2024 Mar; 63(3):402-404. PubMed ID: 38229523
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.
    Sánchez-García V; Navarro-Triviño FJ; Silvestre JF
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1426-e1429. PubMed ID: 37458506
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab.
    Cioppa V; Lazzeri L; Carraro A; De Piano E; Falcinelli F; Galluzzo M; Pallotta S; De Pità O; Russo F
    Dermatitis; 2024; 35(S1):S107-S108. PubMed ID: 37594754
    [No Abstract]   [Full Text] [Related]  

  • 6. Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study.
    Kang DH; Kwon SH; Lew BL
    J Dermatol; 2024 Mar; 51(3):e63-e65. PubMed ID: 37950501
    [No Abstract]   [Full Text] [Related]  

  • 7. Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol; 2023 Jul; 189(2):e39. PubMed ID: 37459131
    [No Abstract]   [Full Text] [Related]  

  • 8. Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients.
    Achten R; Thijs J; van Luijk C; Knol E; Delemarre E; de Graaf M; Bakker D; de Boer J; van Wijk F; de Bruin-Weller M
    Clin Exp Allergy; 2023 Feb; 53(2):239-243. PubMed ID: 36550628
    [No Abstract]   [Full Text] [Related]  

  • 9. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
    Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J
    Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359
    [No Abstract]   [Full Text] [Related]  

  • 10. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
    Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Gurioli C; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Esposito M; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
    J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e384-e388. PubMed ID: 36225088
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review.
    Akuffo-Addo E; Nicholas MN; Lansang P
    J Cutan Med Surg; 2023; 27(2):177-178. PubMed ID: 36721993
    [No Abstract]   [Full Text] [Related]  

  • 13. Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis.
    Blauvelt A
    JAMA Dermatol; 2024 Mar; 160(3):370. PubMed ID: 38353963
    [No Abstract]   [Full Text] [Related]  

  • 14. Dupilumab therapy in children aged 2-12 years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study.
    Zhou B; Peng C; Cao Q; Wang J; Chen X; Li J
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e35-e38. PubMed ID: 37565387
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study.
    Guédon C; Tauber M; Linder C; Paul C; Shourick J
    Ann Dermatol Venereol; 2023 Sep; 150(3):215-216. PubMed ID: 37598014
    [No Abstract]   [Full Text] [Related]  

  • 17. Dupilumab alleviates pruritus regardless of skin improvement in adults with atopic dermatitis: A cohort study.
    Chen YW; Chen HH; Huang WN; Hsu CY; Chen YH; Hung WT; Tang KT
    J Am Acad Dermatol; 2024 Jan; 90(1):195-196. PubMed ID: 37751779
    [No Abstract]   [Full Text] [Related]  

  • 18. Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis.
    Cunningham KN; Alsukait S; Cohen SR; Learned C; Gao DX; Kachuk C; Dumont N; Zipeto A; Rosmarin D
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e765-e767. PubMed ID: 36688247
    [No Abstract]   [Full Text] [Related]  

  • 19. Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects.
    Lasheras-Pérez MA; Palacios-Diaz RD; Pozuelo-Ruiz M; Torres-Navarro I; Botella-Estrada R; Rodriguez-Serna M
    Int J Dermatol; 2024 Jan; 63(1):105-107. PubMed ID: 38014601
    [No Abstract]   [Full Text] [Related]  

  • 20. Moderate-to-severe atopic dermatitis in different age groups treated with dupilumab in China.
    Song X; Liu B; Luan T; Liao S; Tan Y; Peng C; Zhao Z
    Allergy; 2023 Jun; 78(6):1696-1699. PubMed ID: 36708064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.